Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.51 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26869129 | 1.00 | HRH3 (0.51) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL22996703 | 0.85 | HRH3 (0.49) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL12122183 | 0.82 | HRH3 (0.53) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL16000539 | 0.82 | HRH3 (0.53) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL16000538 | 0.82 | HRH3 (0.53) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL22893242 | 0.82 | HRH3 (0.47) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL24700866 | 0.82 | HRH3 (0.47) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL26194411 | 0.81 | HRH3 (0.46) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL24139725 | 0.81 | HRH3 (0.51) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL24498744 | 0.81 | HRH3 (0.51) | HRH3CCR2KCNH2CHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-09 | — | — | US | disclosed |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-09 | — | — | US | disclosed |
| WO-2023125989-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-11014884-B2 | Modulators of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-12-31 | — | — | US | disclosed |
| US-20200140384-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-05-07 | — | — | US | disclosed |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20170258751-A1 | METHODS OF TREATING HEART FAILURE USING FATTY ACID FUMARATE DERIVATIVES | RAJASEKHAR VIJAYKUMAR (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170044112-A1 | HYDROPHOBICALLY TAGGED JANUS KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258751-A1 | METHODS OF TREATING HEART FAILURE USING FATTY ACID FUMARATE DERIVATIVES | FH, FABP3, HMGCR | HRH3 3308/4885CCR2 4364/4885KCNH2 2826/4885 |
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | HRH3 668/4885CCR2 4674/4885KCNH2 589/4885 |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | HRH3 2810/4885CCR2 3123/4885KCNH2 4610/4885 |
| US-11014884-B2 | Modulators of hemoglobin | HBG1, HBG2, HBB | HRH3 4388/4885CCR2 4726/4885KCNH2 4253/4885 |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | HRH3 3422/4885CCR2 3646/4885KCNH2 4576/4885 |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | HRH3 1249/4885CCR2 3699/4885KCNH2 4390/4885 |
| US-20200140384-A1 | MODULATORS OF HEMOGLOBIN | HBG1, HBG2, HBB | HRH3 4388/4885CCR2 4726/4885KCNH2 4253/4885 |
| US-20170044112-A1 | HYDROPHOBICALLY TAGGED JANUS KINASE INHIBITORS AND USES THEREOF | JAK1, JAK3, JAK2 | HRH3 525/4885CCR2 1715/4885KCNH2 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.